Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...

Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect ...

Aside from the layoffs, InflaRx will deprioritize Gohibic, a COVID-19 antibody that was granted emergency use authorization ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

The closure, broken by Endpoints News on Thursday after speaking with two former employees, appears to have officially ...

While venture capital funding dipped to a six-year low in 2025, it nevertheless remained above pre-pandemic levels for ...

A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

The Beltway-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...

The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...

Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular ...